BACKGROUND: Nuclear magnetic resonance (NMR) spectra of serum obtained under quantitative conditions for lipoprotein particle analyses contain additional signals that could potentially serve as useful clinical biomarkers. One of these signals that we named GlycA originates from a subset of glycan N-acetylglucosamine residues on enzymatically glycosylated acute-phase proteins. We hypothesized that the amplitude of the GlycA signal might provide a unique and convenient measure of systemic inflammation. METHODS: We developed a spectral deconvolution algorithm to quantify GlycA signal amplitudes from automated NMR LipoProfile(®) test spectra and assessed analytic precision and biological variability. Spectra of acute-phase glycoproteins and serum fractions were analyzed to probe the origins of the GlycA signal. GlycA concentrations obtained from archived NMR LipoProfile spectra of baseline plasma from 5537 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) were used to assess associations with demographic and laboratory parameters including measures of inflammation. RESULTS: Major acute-phase protein contributors to the serum GlycA signal are α1-acid glycoprotein, haptoglobin, α1-antitrypsin, α1-antichymotrypsin, and transferrin. GlycA concentrations were correlated with high-sensitivity C-reactive protein (hsCRP) (r = 0.56), fibrinogen (r = 0.46), and interleukin-6 (IL-6) (r = 0.35) (all P < 0.0001). Analytic imprecision was low (intra- and interassay CVs 1.9% and 2.6%, respectively) and intraindividual variability, assessed weekly for 5 weeks in 23 healthy volunteers, was 4.3%, lower than for hsCRP (29.2%), cholesterol (5.7%), and triglycerides (18.0%). CONCLUSIONS: GlycA is a unique inflammatory biomarker with analytic and clinical attributes that may complement or provide advantages over existing clinical markers of systemic inflammation.
BACKGROUND: Nuclear magnetic resonance (NMR) spectra of serum obtained under quantitative conditions for lipoprotein particle analyses contain additional signals that could potentially serve as useful clinical biomarkers. One of these signals that we named GlycA originates from a subset of glycan N-acetylglucosamine residues on enzymatically glycosylated acute-phase proteins. We hypothesized that the amplitude of the GlycA signal might provide a unique and convenient measure of systemic inflammation. METHODS: We developed a spectral deconvolution algorithm to quantify GlycA signal amplitudes from automated NMR LipoProfile(®) test spectra and assessed analytic precision and biological variability. Spectra of acute-phase glycoproteins and serum fractions were analyzed to probe the origins of the GlycA signal. GlycA concentrations obtained from archived NMR LipoProfile spectra of baseline plasma from 5537 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) were used to assess associations with demographic and laboratory parameters including measures of inflammation. RESULTS: Major acute-phase protein contributors to the serum GlycA signal are α1-acid glycoprotein, haptoglobin, α1-antitrypsin, α1-antichymotrypsin, and transferrin. GlycA concentrations were correlated with high-sensitivity C-reactive protein (hsCRP) (r = 0.56), fibrinogen (r = 0.46), and interleukin-6 (IL-6) (r = 0.35) (all P < 0.0001). Analytic imprecision was low (intra- and interassay CVs 1.9% and 2.6%, respectively) and intraindividual variability, assessed weekly for 5 weeks in 23 healthy volunteers, was 4.3%, lower than for hsCRP (29.2%), cholesterol (5.7%), and triglycerides (18.0%). CONCLUSIONS: GlycA is a unique inflammatory biomarker with analytic and clinical attributes that may complement or provide advantages over existing clinical markers of systemic inflammation.
Authors: Daniela Baumstark; Werner Kremer; Alfred Boettcher; Christina Schreier; Paul Sander; Gerd Schmitz; Renate Kirchhoefer; Fritz Huber; Hans Robert Kalbitzer Journal: J Lipid Res Date: 2019-06-25 Impact factor: 5.922
Authors: Akintunde O Akinkuolie; Aruna D Pradhan; Julie E Buring; Paul M Ridker; Samia Mora Journal: Arterioscler Thromb Vasc Biol Date: 2015-04-23 Impact factor: 8.311
Authors: James D Otvos; John R Guyton; Margery A Connelly; Sydney Akapame; Vera Bittner; Steven L Kopecky; Megan Lacy; Santica M Marcovina; Joseph B Muhlestein; William E Boden Journal: J Clin Lipidol Date: 2018-01-12 Impact factor: 4.766
Authors: Shafqat Ahmad; Samia Mora; Paul M Ridker; Frank B Hu; Daniel I Chasman Journal: Arterioscler Thromb Vasc Biol Date: 2019-01 Impact factor: 8.311
Authors: Patrick R Lawler; Akintunde O Akinkuolie; Paulette D Chandler; M Vinayaga Moorthy; Martin J Vandenburgh; Debra A Schaumberg; I-Min Lee; Robert J Glynn; Paul M Ridker; Julie E Buring; Samia Mora Journal: Circ Res Date: 2016-03-07 Impact factor: 17.367
Authors: Eve-Marie A Benson; Martin Tibuakuu; Di Zhao; Akintunde O Akinkuolie; James D Otvos; Daniel A Duprez; David R Jacobs; Samia Mora; Erin D Michos Journal: Clin Cardiol Date: 2018-11-19 Impact factor: 2.882
Authors: Toma Keser; Ivan Gornik; Frano Vučković; Najda Selak; Tamara Pavić; Edita Lukić; Ivan Gudelj; Hrvoje Gašparović; Bojan Biočina; Therese Tilin; Annika Wennerström; Satu Männistö; Veikko Salomaa; Aki Havulinna; Wei Wang; James F Wilson; Nish Chaturvedi; Markus Perola; Harry Campbell; Gordan Lauc; Olga Gornik Journal: Diabetologia Date: 2017-09-13 Impact factor: 10.122